MIGENIX, Inc., (MGIFF) has been notified by Cutanea Life Sciences, Inc.,
(Cutanea), its development and commercialization partner for CLS001
(topical omiganan), of the initiation of a phase II clinical study in the
treatment of rosacea.
This study is being conducted in the United States by Cutanea, and is
expected to be completed by the end of 2007.
source >
http://tinyurl.com/2xkk6t
BB
Yahoo! Groups TipsDid you know...Message search is now enhanced, find messages faster. Take it for a spin. |
Having problems with message search?
Fill out this form to ensure your group is one of the first to be migrated to the new message search system.
|
Offline 
Send Email